Details for Patent: 12,152,028
✉ Email this page to a colleague
Which drugs does patent 12,152,028 protect, and when does it expire?
Patent 12,152,028 protects LIFYORLI (COPACKAGED) and is included in one NDA.
This patent has twelve patent family members in nine countries.
Summary for Patent: 12,152,028
| Title: | Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| Abstract: | The present invention provides methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators, and compositions having low impurity levels. |
| Inventor(s): | Jeffrey Mark Dener, Hazel Joan HUNT, Travis Lemons, Gary Reid, Kilian GARREC, Thomas C. Stephens, Adam Daisuke GAMMACK YAMAGATA, Yunguo LU |
| Assignee: | Corcept Therapeutics Inc |
| Application Number: | US17/560,048 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 12,152,028
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Corcept Therap | LIFYORLI (COPACKAGED) | relacorilant | CAPSULE;ORAL | 220641-001 | Mar 25, 2026 | RX | Yes | Yes | 12,152,028 | ⤷ Start Trial | Y | TREATMENT OF PLATINUM-RESISTANT EPITHELIAL OVARIAN CANCER WITH LIFYORLI IN COMBINATION WITH NAB-PACLITAXEL, IN ADULTS WHO HAVE RECEIVED ONE TO THREE PRIOR SYSTEMIC TREATMENT REGIMENS, AT LEAST ONE OF WHICH INCLUDED BEVACIZUMAB | ⤷ Start Trial | |||
| Corcept Therap | LIFYORLI (COPACKAGED) | relacorilant | CAPSULE;ORAL | 220641-001 | Mar 25, 2026 | RX | Yes | Yes | 12,152,028 | ⤷ Start Trial | Y | TREATMENT OF PLATINUM-RESISTANT FALLOPIAN TUBE CANCER WITH LIFYORLI IN COMBINATION WITH NAB-PACLITAXEL, IN ADULTS WHO HAVE RECEIVED ONE TO THREE PRIOR SYSTEMIC TREATMENT REGIMENS, AT LEAST ONE OF WHICH INCLUDED BEVACIZUMAB | ⤷ Start Trial | |||
| Corcept Therap | LIFYORLI (COPACKAGED) | relacorilant | CAPSULE;ORAL | 220641-001 | Mar 25, 2026 | RX | Yes | Yes | 12,152,028 | ⤷ Start Trial | Y | TREATMENT OF PLATINUM-RESISTANT PRIMARY PERITONEAL CANCER WITH LIFYORLI IN COMBINATION WITH NAB-PACLITAXEL, IN ADULTS WHO HAVE RECEIVED ONE TO THREE PRIOR SYSTEMIC TREATMENT REGIMENS, AT LEAST ONE OF WHICH INCLUDED BEVACIZUMAB | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,152,028
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2021410756 | ⤷ Start Trial | |||
| Australia | 2025203341 | ⤷ Start Trial | |||
| Canada | 3202354 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
